Because the roles of IFN-γ in pre-LSC and LSC function in MDS and AML are still unclear, further preclinical investigation with in vivo models is needed to better understand the appropriate clinical setting for targeting IFN-γ signaling in these diseases. The gene discussed is IFNG; the disease is acute myeloid leukemia.